Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin para-hydroxylation

被引：0
|
作者：
Schmider, J [1 ]
Greenblatt, DJ [1 ]
vonMoltke, LL [1 ]
Karsov, D [1 ]
Shader, RI [1 ]
机构：
[1] TUFTS UNIV,SCH MED,BOSTON,MA 02111
来源：
PSYCHOPHARMACOLOGY BULLETIN | 1996年 / 32卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：511 / 511
页数：1
相关论文
共 50 条
  • [21] CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment
    Silvado, Carlos Eduardo
    Terra, Vera Cristina
    Twardowschy, Carlos Alexandre
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2018, 11 : 51 - 58
  • [22] The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
    Mamiya, K
    Ieiri, I
    Shimamoto, J
    Yukawa, E
    Imai, J
    Ninomiya, H
    Yamada, H
    Otsubo, K
    Higuchi, S
    Tashiro, N
    EPILEPSIA, 1998, 39 (12) : 1317 - 1323
  • [23] CYP2C9 inhibition: Impact of probe selection and pharmacogenetics on in vitro inhibition profiles
    Kumar, Vikas
    Wahlstrom, Jan L.
    Rock, Dan A.
    Warren, Chad J.
    Gorman, Lee A.
    Tracy, Timothy S.
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (12) : 1966 - 1975
  • [24] Effect of Ginkgo on CYP2C9: In vitro and in vivo studies.
    Greenblatt, DJ
    von Moltke, LL
    Perloff, ES
    Luo, Y
    Harmatz, JS
    Bedir, E
    Khan, IA
    Goldman, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P48 - P48
  • [25] Effects of mutations in CYP2C9 and CYP2C19 genes on phenytoin dose
    Kijsanayotin, Pornpimol
    Cloyd, James C.
    Leppik, Ilo E.
    Birnbaum, Angela K.
    Prassitisopin, Baralee
    Ramsay, R. Eugene
    Rarick, John O.
    Mishra, Usha
    White, James R.
    Marino, Susan E.
    Conway, Jeannine M.
    Oetting, William S.
    NEUROLOGY, 2007, 68 (12) : A212 - A212
  • [26] Involvement of CYP2C9 on chlorpropamide 2-hydroxylation in human:: In vitro and in vivo evidence.
    Shon, JH
    Yoon, YR
    Kim, MJ
    Cha, IJ
    Shin, JG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P41 - P41
  • [27] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Shaul, Chanan
    Blotnick, Simcha
    Adar, Liat
    Muszkat, Mordechai
    Bialer, Meir
    Caraco, Yoseph
    CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1187 - 1198
  • [28] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Chanan Shaul
    Simcha Blotnick
    Liat Adar
    Mordechai Muszkat
    Meir Bialer
    Yoseph Caraco
    Clinical Pharmacokinetics, 2022, 61 : 1187 - 1198
  • [29] Inhibition of selective serotonin reuptake inhibitors on vesicular monoamine transporter 2
    Tamura, Kohei
    Tatsumi, Kuniko
    Yasumoto, Satoshi
    Yamamoto, Toshifumi
    Ikeda, Kazutaka
    Yamamoto, Hideko
    NEUROSCIENCE RESEARCH, 2007, 58 : S78 - S78
  • [30] CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects
    Franco, Valentina
    Perucca, Emilio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (08) : 1269 - 1279
12345